Ascentage Pharma Group Corp. Ltd. has priced the first IPO of the year in the U.S. The offering of 7.32 million shares has the Suzhou, China, and Rockville, Md.-based company looking for gross proceeds of about $126.4 million, assuming a price of $17.25 per share.

Biopharmas raising money in public or private financings, including: Disc Medicine.

Biopharmas raising money in public or private financings, including: Belhaven, Bioxytran, Dermata, Hepion, Nurexone, Okyo, Sen-Jam.

Icelandic genomics company Arctic Therapeutics has closed a €26.5 million (US$27.6 million) series A, enabling it to assess if its lead drug AT-001, designed to treat a rare inherited amyloid disease, also could be used to treat more common forms of dementia, including Alzheimer’s disease. The program is currently in a phase IIb/III European trial in cystatin C amyloid angiopathy, an ultra-rare disease found only in Iceland that is caused by the L68Q mutation in the cystatin C gene.

Biopharmas raising money in public or private financings, including: Ascentage, Immunovia, Kane Biotech, Odyssey, Quantum, Sionna.

While Moderna Inc. plans to cut its expenses by $1 billion in 2025, the company has received a little breathing room by a hefty U.S. Department of Health and Human Services (HHS) grant. The Biomedical Advanced Research and Development Authority awarded Moderna roughly $590 million to support late-stage development of its mRNA-based avian-variant vaccines and to increase the number of clinical trials for another five additional subtypes of pre-pandemic influenza.

Biopharmas raising money in public or private financings, including: Phio.

Biopharmas raising money in public or private financings, including: Silexion.

Biopharmas raising money in public or private financings, including: Azitra, Be Biopharma, Hinge Bio, Iongen, Kazia.

Biopharmas raising money in public or private financings, including: Inhibrx, Phio, Provectus, Umoja, Visirose.